Grant: Alliance Grants
Institut national de la recherche scientifique
$30,000.00
Chemical synthesis, isolation, purification and in vivo properties of anthocycanins - FRQNT-Team supplements grant_x000d_ _x000d_ _x000d_
FY 2020-21
Summary
Alzheimer's disease (AD) is one of the most severe socio-economical and medical burdens worldwide. In Canada, around 750,000 people are affected by dementia (~7% of people aged 65+ years) and its overall cost is estimated to $Bn 12.2 (~1% of Canada GDP). This burden is constantly growing as prevalence of AD doubles every 5 years among people aged 65+ years. Current treatment for AD are only symptomatic and only 25-50% of patients respond to these treatments. We and others have demonstrated that some naturally available polyphenolic compounds could efficiently prevent multiple AD pathogenic mechanisms in the brain and even through the gut-brain axis. We have recently developed a proprietary formulation (MAF14001) of four specific polyphenols that showed to be a good candidate as treatment for AD. Our results suggest that the administration of MAF14001 formulation limits the spatial memory decline. However, the plasma concentrations remained relatively low and varied considerably, constituting an obstacle to efficacious polyphenols-based treatment. These observations are aligned with widespread observations that bioavailabity of polyphenols is a common limitation to their efficacy, due to chemical unstability in physiological environment and poor absorption.
To remediate these issues, several strategies have already been tested successfully, particularly the incorporation of the phenolic compounds into emulsions to decrease their degradations throughout the gastro-intestinal tract and increase their absorption. Double emulsions of "Water-in-Oil-in-Water" (W1/O/W2) type are the best suited candidates for effective delivery of the polyphenolic compound.
Therefore, we hypothesize that the incorporation of the formulation MAF14001 into a food-grade double-emulsion will enhance the bioaccessibility, the absorption and thus its effects on cognitive function of an AD mouse model.
Program
Alliance Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
560899-2020
Name nom
RAMASSAMY, Charles
Department département
INRS-Institut Armand-Frappier, Centre
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
6101
Research subject group en
Food science and technology
Research subject group fr
Science et technologie de l'alimentation
Research subject en
Food chemistry and analysis
Research subject fr
Chimie alimentaire et analyse
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Chemical synthesis, isolation, purification and in vivo properties of anthocycanins - FRQNT-Team supplements grant_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
Alzheimer's disease (AD) is one of the most severe socio-economical and medical burdens worldwide. In Canada, around 750,000 people are affected by dementia (~7% of people aged 65+ years) and its overall cost is estimated to $Bn 12.2 (~1% of Canada GDP). This burden is constantly growing as prevalence of AD doubles every 5 years among people aged 65+ years. Current treatment for AD are only symptomatic and only 25-50% of patients respond to these treatments. We and others have demonstrated that some naturally available polyphenolic compounds could efficiently prevent multiple AD pathogenic mechanisms in the brain and even through the gut-brain axis. We have recently developed a proprietary formulation (MAF14001) of four specific polyphenols that showed to be a good candidate as treatment for AD. Our results suggest that the administration of MAF14001 formulation limits the spatial memory decline. However, the plasma concentrations remained relatively low and varied considerably, constituting an obstacle to efficacious polyphenols-based treatment. These observations are aligned with widespread observations that bioavailabity of polyphenols is a common limitation to their efficacy, due to chemical unstability in physiological environment and poor absorption.
To remediate these issues, several strategies have already been tested successfully, particularly the incorporation of the phenolic compounds into emulsions to decrease their degradations throughout the gastro-intestinal tract and increase their absorption. Double emulsions of "Water-in-Oil-in-Water" (W1/O/W2) type are the best suited candidates for effective delivery of the polyphenolic compound.
Therefore, we hypothesize that the incorporation of the formulation MAF14001 into a food-grade double-emulsion will enhance the bioaccessibility, the absorption and thus its effects on cognitive function of an AD mouse model.